Status:
COMPLETED
Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex
Lead Sponsor:
Universidade Federal do Rio de Janeiro
Collaborating Sponsors:
Hospital Federal de Bonsucesso
Conditions:
Neuromuscular Blockade
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The aim of this study is to determine the recovery time of moderate neuromuscular blockade with sugammadex in adults pretreated with magnesium sulfate.
Detailed Description
Sugammadex is a novel neuromuscular blocking reversal agent. Its mechanism of action is the encapsulation of rocuronium and vecuronium molecules. Numerous studies show a potential role of magnesium in...
Eligibility Criteria
Inclusion
- Age 18-65 years
- ASA physical status 1 or 2
- weight BMI 18.5-24.9
- otorhinolaryngological surgeries
Exclusion
- major surgery associated with massive blood loss or fluid replacement
- any known allergy to magnesium sulphate or any other study drugs
- pregnant
- anatomical malformations expected to result in a difficult intubation;
- known or suspected neuromuscular disorders and/or significant hepatic or renal dysfunction
- administration of any medication known to interfere with neuromuscular blocking agents (such as anticonvulsants, aminoglycosides, calcium channel blockers and magnesium containing medications)
- hypomagnesemia, hypermagnesemia, hypocalcemia, hypercalcemia
Key Trial Info
Start Date :
October 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01828385
Start Date
October 1 2012
End Date
February 1 2013
Last Update
January 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Federal de Bonsucesso
Rio de Janeiro, Rio de Janeiro, Brazil, 21041-030